Trial · NCT02669121
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 96
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 45 | 2,357 | |
| other | Upper respiratory tract infection | Infections and infestations | NoV GI.1/GII.4 Bivalent VLP Vaccine | 57 | 2,355 | |
| other | Procedural pain | Injury, poisoning and procedural complications | Placebo | 57 | 2,357 | |
| other | Procedural pain | Injury, poisoning and procedural complications | NoV GI.1/GII.4 Bivalent VLP Vaccine | 55 | 2,355 | |
| serious | Microcytic anaemia | Blood and lymphatic system disorders | Placebo | 1 | 2,357 | |
| serious | Microcytic anaemia | Blood and lymphatic system disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 0 | 2,355 | |
| serious | Pancytopenia | Blood and lymphatic system disorders | Placebo | 0 | 2,357 | |
| serious | Pancytopenia | Blood and lymphatic system disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 1 | 2,355 | |
| serious | Constipation | Gastrointestinal disorders | Placebo | 1 | 2,357 | |
| serious | Constipation | Gastrointestinal disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 0 | 2,355 | |
| serious | Crohn's disease | Gastrointestinal disorders | Placebo | 0 | 2,357 | |
| serious | Crohn's disease | Gastrointestinal disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 1 | 2,355 | |
| serious | Oesophagitis | Gastrointestinal disorders | Placebo | 1 | 2,357 | |
| serious | Oesophagitis | Gastrointestinal disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 0 | 2,355 | |
| serious | Non-cardiac chest pain | General disorders | Placebo | 1 | 2,357 | |
| serious | Non-cardiac chest pain | General disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 0 | 2,355 | |
| serious | Pyrexia | General disorders | Placebo | 1 | 2,357 | |
| serious | Pyrexia | General disorders | NoV GI.1/GII.4 Bivalent VLP Vaccine | 0 | 2,355 | |
| serious | Pneumonia | Infections and infestations | Placebo | 3 | 2,357 | |
| serious | Pneumonia | Infections and infestations | NoV GI.1/GII.4 Bivalent VLP Vaccine | 2 | 2,355 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02669121/events